SEHK:6990Biotechs
Is Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Cheap As ADC Pipeline News Builds?
Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) is back in focus after Chinese regulators accepted a new indication application for its TROP2-directed ADC sacituzumab tirumotecan in first-line triple-negative breast cancer.
See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical.
The regulatory momentum around sacituzumab tirumotecan and SKB565 comes alongside a 26.81% year to date share price return and a very large 3 year total shareholder return of about 7x. This suggests...